Covid 19 Update

A message to our customers and partners:

Vector Laboratories is continuously monitoring and assessing the current situation with respect to the coronavirus (COVID-19) outbreak and responding appropriately as it evolves.

As COVID-19 continues to impact our communities, we are mindful that there may be concerns regarding ordering and general delays. Our commitment is to remain in operation in order to supply mission critical products to our customers and partners. We have an active response plan to the COVID-19 pandemic in place to ensure the safety of our workforce and delivery of product to our customers.

Currently, our efforts are enabling critical research by providing high-quality and efficient delivery of reagents for immunohistochemistry, immunofluorescence, bioconjugation, and glycobiology. We provide critical reagents that are making an immediate impact in global health and safety, and we are doing everything in our power to maintain business as usual.

Impact to Manufacturing and Supply:

Our facility remains open and operational. Our manufacturing and support teams are maintaining tight communication and working closely with our suppliers to ensure uninterrupted manufacturing workflows. Currently, we are experiencing minimal supply chain disruptions. If we encounter any issues, we will communicate with impacted customers on a case-by-case basis. Please reach out to our Customer Service Team with any questions or concerns.

Within our manufacturing facility, we are following the guidelines of local and national health organizations in order to mitigate the spread of COVID-19.

Impact to Business Operations:

Vector Laboratories is taking all recommended precautions to ensure that we keep our employees and their families safe, while maintaining our business continuity in support of our customers. Our customer service and order fulfillment teams continue to operate to ensure that all customer orders are processed promptly and that we continue to meet our customers’ expectations. Workplace recommendations by WHO, CDC, and local and national authorities are being implemented, including:

• Hosting virtual alternatives to meetings and conferences
• Heightening hygiene protocols
• Requiring all visitors and contractors to be vaccinated or test negative for COVID-19 before they enter the facility

If you have any questions or concerns, please email us at [email protected] or [email protected]. We are also available by phone at +1 (800) 227-6666 or +1(650) 697-3600.